Depression: all studies (page 147) - The Consciousness Library

Fabrication of a Controlled-Release Core-Shell Floating Tablet of Ketamine Hydrochloride Using a 3D Printing Technique for Management of Refractory Depressions and Chronic Pain.

Polymers March 8, 2024 Tahmineh Karami, Emad Ghobadi, Mohammad Akrami et al. 13 citations

In this study, a novel floating, controlled-release and core-shell oral tablet of ketamine hydrochloride (HCl) was produced using a dual extrusion by 3D printing method. A mixture of Soluplus® and Eudragit® RS-PO was extruded by a hot-melt extrusion (HME) nozzle at 150-160 °C to fabricate the tablet shell, while a second nozzle known as a pressure-assisted syringe (PAS) extruded the etamine HCl...

DOI: 10.3390/polym16060746 Full text Ketamine 3d printing Additive manufacturing Extended release +7

New evidence for flexible psilocybin dosing in patients with treatment-resistant depression.

Med March 8, 2024 Scott T Aaronson, Zofia Kozak 1 citation

Psilocybin has demonstrated efficacy for treating depression; however, psychiatrically complex patients have been excluded from trials. A recent clinical trial by Rosenblat at al.1 demonstrates feasibility of a flexible dosing schedule of psilocybin in individuals with severely treatment-resistant depression (TRD), including those with co-morbid conditions or bipolar II disorder (BPII),...

DOI: 10.1016/j.medj.2024.01.014 Full text Treatment-resistant depression Psychedelic therapy Personalized medicine Depression treatment +1

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.

Med March 8, 2024 Joshua D. Rosenblat, Shakila Meshkat, Zoe Doyle et al. 97 citations

Psilocybin-assisted psychotherapy (PAP) has been associated with antidepressant effects. Trials to date have typically excluded participants with complex presentations. Our aim was to determine the feasibility of PAP in a complex population, including high levels of treatment resistance in major depressive and bipolar disorder and patients with baseline suicidality and significant comorbidity....

DOI: 10.1016/j.medj.2024.01.005 Full text Major depressive disorder Treatment-resistant depression Psychedelic therapy Translation to patients +11

Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder

International Journal of Mental Health and Addiction March 7, 2024 Brandon Weiss, Leor Roseman, Bruna Giribaldi et al. 26 citations

Abstract The mechanisms by which Psilocybin Therapy (PT) improves depression remain an important object of study, with scientists actively exploring acute psychological experiences and neurobiological processes as candidates. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we investigated whether...

DOI: 10.1007/s11469-024-01253-9 Full text Major depressive disorder Mystical experience Ego dissolution Psilocybin therapy psilocybin +7

EMBARK Psychedelic Therapy for Depression

March 6, 2024 Bill Brennan, Alex Belser 6 citations

Abstract EMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person is a comprehensive guidebook for clinicians that presents a novel therapeutic framework for administering psychedelic medicines. The EMBARK model was developed in response to the growing interest in psychedelic medicines for treating mental health disorders, particularly depression, and the identified gaps...

DOI: 10.1093/9780197762622.001.0001

Perioperative Adjunctive Esketamine for Postpartum Depression Among Women Undergoing Elective Cesarean Delivery

JAMA Network Open March 6, 2024 Yu Chen, Yu Guo, Han Wu et al. 63 citations

Importance Postpartum depression (PPD) is one of the most common mental health conditions during the perinatal and postpartum periods, which can have adverse effects on both mother and infant. Objective To investigate the efficacy of perioperative adjunctive esketamine administration after cesarean deliveries in the prevention of PPD. Design, Setting, and Participants A single-center,...

DOI: 10.1001/jamanetworkopen.2024.0953 Full text Postpartum-depression Cesarean-section Mental-health Maternal-health +1

A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide.

Psychopharmacology Bulletin March 4, 2024 Timothy Whitaker, Kimberly F Farrand, Michael E. Thase 249 citations

Despite the prevalence of Major Depressive Disorder (MDD) and the propensity of affected individuals to eventually die by suicide, there is no therapeutic approved specifically for suicidal ideation and behavior (SI/B) in MDD. The NMDA receptor antagonist ketamine has been investigated for the treatment of depression and shown to have a rapid effect on symptoms. Spravato® (esketamine) is...

DOI: 10.1016/j.jad.2020.09.007 Full text Major depressive disorder Racemic ketamine Intranasal Open label +3

A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder

Brain Sciences March 3, 2024 Mario Renato Velit-Salazar, Eloise Cherian, Paulo R Shiroma 13 citations

Objective: This study aims to provide an overview of pharmacological trials that examine the neurocognitive effects of psychedelics among healthy individuals and patients with post-traumatic stress disorder (PTSD) or major depressive disorder (MDD). Methods: The Preferred Reporting Items for Systematic Reviews (PRISMA) was used as a guide to structure and report the findings for this review. A...

DOI: 10.3390/brainsci14030248 MDMA Psilocybin Mescaline Cannabis +7

Depression-like phenotypes in mice following common bile duct ligation: Insights into the gut-liver-brain axis via the vagus nerve.

Neurobiology of Disease March 1, 2024 Yong Yang, Akifumi Eguchi, Chisato Mori et al.

Depression frequently occurs in patients with liver cirrhosis, yet the reasons for this correlation are not fully understood. Dysbiosis of gut microbiota has been implicated in depression through the gut-brain axis via the vagus nerve. This study explored the potential role of the gut-liver-brain axis via the vagus nerve in depression-like phenotypes in mice with liver cirrhosis. These mice...

DOI: 10.1016/j.nbd.2024.106433 Full text Arketamine Depression Gut microbiota Liver cirrhosis +2

Novel rapid treatment options for adolescent depression.

Pharmacological Research March 1, 2024 Sandra Ledesma-Corvi, Jordi Jornet-Plaza, Laura Gálvez-melero et al. 22 citations

There is an urgent need for novel fast-acting antidepressants for adolescent treatment-resistant depression and/or suicidal risk, since the selective serotonin reuptake inhibitors that are clinically approved for that age (i.e., fluoxetine or escitalopram) take weeks to work. In this context, one of the main research lines of our group is to characterize at the preclinical level novel...

DOI: 10.1016/j.phrs.2024.107085 Full text Depression Adolescence Fast-acting antidepressants Sex differences +1